Annemarie E Fogerty1, Jean M Connors. 1. Department of Hematology/Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA.
Abstract
PURPOSE OF REVIEW: This review summarizes the currently available data concerning risk and management of venous thromboembolism in pregnant women with inherited thrombophilia. SUMMARY: Pregnancy is a hypercoagulable state, and inherited thrombophilia increases this risk further. Despite the risks, the actual incidence of venous thromboembolism remains low, and therefore, the widespread use of anticoagulants for pregnant women with inherited thrombophilia is not advised. Although randomized, placebo-controlled trials investigating the risks and benefits of anticoagulation have not been performed, there are data to support the use of low molecular weight heparin for high and intermediate-risk women. We will review these data and treatment recommendations, which are based on retrospective and case-control studies as well as expert opinion and consensus statements.
PURPOSE OF REVIEW: This review summarizes the currently available data concerning risk and management of venous thromboembolism in pregnant women with inherited thrombophilia. SUMMARY: Pregnancy is a hypercoagulable state, and inherited thrombophilia increases this risk further. Despite the risks, the actual incidence of venous thromboembolism remains low, and therefore, the widespread use of anticoagulants for pregnant women with inherited thrombophilia is not advised. Although randomized, placebo-controlled trials investigating the risks and benefits of anticoagulation have not been performed, there are data to support the use of low molecular weight heparin for high and intermediate-risk women. We will review these data and treatment recommendations, which are based on retrospective and case-control studies as well as expert opinion and consensus statements.